OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

Related Articles

Immunome's $4.39 Million Insider Sale: A Pre-Planned Exit Amidst Robust Pipeline Momentum

1 months ago

Allbirds' $39 Million Sale: A Cautionary Tale for the IPO Class of 2021

4 months ago

Enliven Therapeutics' Soaring Stock Faces a $570,000 Insider Reality Check

1 months ago

Is Enliven Therapeutics (ELVN) a Buy After Its Upsized Offering and Positive Clinical Data

2 months ago

Category

You may also like

Stock News•2 weeks ago

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Remedium Bio raised $10 million in Series A financing, led by Lifespan Vision Ventures, which completed the round. The funding could accelerate development of its gene therapy platform.

Share

Stock News•2 weeks ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics reported Q2 2026 results with $895M cash, extending runway into 2030, after positive Phase 1 data for ELVN-001 in CML and FDA alignment on Phase 3 design.

ELVN

Share

Stock News•1 months ago

Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates

Assembly Biosciences holds over $340M in pro forma liquidity post-offering, backed by a Gilead partnership, supporting operations through 2028 without near-term capital needs.

ASMB

Share

Stock News•1 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.

ABBV

Share